Achieve Life Sciences, Inc. (ACHV)

In the past six months, Achieve Life Sciences' stock has been impacted by financial results, investor concerns, and FDA observations. The company reported its Fourth Quarter and Full Year 2025 financial results on March 24, 2026, meeting forecasted EPS but experiencing a 10.37% pre-market stock drop due to investor concerns over its financial position and future capital needs. The FDA's acceptance of the NDA for cytisinicline with a PDUFA date of June 20, 2026, remains a significant potential catalyst. The stock price as of April 9, 2026, was $3.32 per share, representing a 58.85% increase over the past year, though it has shown volatility in the past three months.

Information regarding specific demand seasonality for Achieve Life Sciences, Inc.'s products and services is not available. As a clinical-stage pharmaceutical company with its primary product still under regulatory review, typical demand seasonality patterns for marketed drugs do not yet apply. Demand for its product, once approved, would likely be driven by public health initiatives, physician prescriptions, and patient awareness campaigns.

Achieve Life Sciences, Inc. is a clinical-stage specialty pharmaceutical company focused on addressing smoking and nicotine addiction. The company is developing and commercializing cytisinicline, a plant-based alkaloid aimed at reducing nicotine withdrawal symptoms and cravings. Achieve Life Sciences has completed Phase 3 studies for smoking cessation and a Phase 2 study for vaping cessation, with its New Drug Application (NDA) for cytisinicline accepted by the FDA with a PDUFA date of June 20, 2026.

Achieve Life Sciences, Inc. is headquartered in Vancouver, Canada, and Bothell, Washington, USA. The company's operations and development efforts for cytisinicline extend to Canada, the United States, and the United Kingdom.

Achieve Life Sciences' reputation has been influenced by its clinical development progress and regulatory interactions for cytisinicline, alongside some challenges. Publication of Phase 3 trial results and data presentations have positively contributed to its scientific standing. However, FDA observations regarding manufacturing issues led to a stock sell-off and a switch to Adare Pharma Solutions as a manufacturing partner. Analysts generally maintain a "Moderate Buy" consensus rating for the stock, with a significant upside potential, suggesting underlying confidence in the product itself.

Achieve Life Sciences, Inc. has a diverse ownership structure. Institutional shareholders hold 43.65% of the stock, individual insiders own 19.56%, and retail investors account for 36.79%. As of April 8, 2026, there were 83 institutional owners holding a total of 23,282,762 shares. Major institutional owners include Franklin Resources Inc., Propel Bio Management, LLC, Vanguard Group Inc., Millennium Management Llc, and Simplify Asset Management Inc. Dialectic Capital Management LP is noted as the largest individual shareholder, owning 3.55 million shares, representing 6.67% of the company.